Blood Res.  2017 Jun;52(2):135-136. 10.5045/br.2017.52.2.135.

Impact of labile plasma iron and iron chelation on the viability of cultured mononuclear cells from patients undergoing autologous hematopoietic stem cell transplantation

• Naoum FA
• Espósito
• Zotarelli Filho IJ

• KMID: 2413332
• DOI: http://doi.org/10.5045/br.2017.52.2.135

Abstract

No abstract available.

MeSH Terms

Hematopoietic Stem Cell Transplantation*
Hematopoietic Stem Cells*
Humans
Iron*
Plasma*
Iron

Figure

• 

  Fig. 1 Changes in the viability of mononuclear cells cultured without the addition of plasma (control), with the addition of autologous plasma with normal LPI levels (LPI normal), with the addition of autologous plasma with increased LPI levels (LPI increased), and with the addition of autologous plasma with increased LPI levels and 50 µM deferiprone (LPI increased+chelator).

Reference

1. Majhail NS, Lazarus HM, Burns LJ. Iron overload in hematopoietic cell transplantation. Bone Marrow Transplant. 2008; 41:997–1003.

2. Evens AM, Mehta J, Gordon LI. Rust and corrosion in hematopoietic stem cell transplantation: the problem of iron and oxidative stress. Bone Marrow Transplant. 2004; 34:561–571.

3. Parkkinen J, Sahlstedt L, von Bonsdorff L, Salo H, Ebeling F, Ruutu T. Effect of repeated apotransferrin administrations on serum iron parameters in patients undergoing myeloablative conditioning and allogeneic stem cell transplantation. Br J Haematol. 2006; 135:228–234.

4. Pullarkat V. Iron overload in patients undergoing hematopoietic stem cell transplantation. Adv Hematol. 2010; 2010:345756.

5. Bradley SJ, Gosriwitana I, Srichairatanakool S, Hider RC, Porter JB. Non-transferrin-bound iron induced by myeloablative chemotherapy. Br J Haematol. 1997; 99:337–343.

6. Naoum FA, Espósito BP, Ruiz LP, et al. Assessment of labile plasma iron in patients who undergo hematopoietic stem cell transplantation. Acta Haematol. 2014; 131:222–226.

7. Dürken M, Agbenu J, Finckh B, et al. Deteriorating free radical-trapping capacity and antioxidant status in plasma during bone marrow transplantation. Bone Marrow Transplant. 1995; 15:757–762.

8. Zhao M, Xie F, Li Y, et al. Increased intracellular concentration of reactive oxygen species mediated the deficient hematopoiesis of iron overload bone marrow. Blood (ASH Annual Meeting Abstracts). 2010; 116:Suppl. abst 4247.

9. Juvonen E, Sahlstedt L, Parkkinen J, Ruutu T. Inhibition of erythroid and granulocyte-macrophage colony formation by non-transferrin-bound iron in vitro: protective effect of apotransferrin. Eur J Haematol. 2007; 79:126–131.

10. Hartmann J, Sinzig U, Wulf G, et al. Evidence for a suppression of the colony forming capacity of erythroid progenitors by iron overload in patients with MDS. Blood (ASH Annual Meeting Abstracts). 2008; 112:Suppl. abst 2694.

11. Jensen PD, Heickendorff L, Pedersen B, et al. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol. 1996; 94:288–299.

12. Glickstein H, Nick H, Cabantchik ZI. Susceptibility of endocrine, cardiac, and macrophage cell lines to iron-mediated oxidative damage and the cytoprotective effect of the orally active chelator deferasirox (Exjade®, ICL670). Blood (ASH Annual Meeting Abstracts). 2007; 110:Suppl. abst 3825.